Patent ductus arteriosus management in very-low-birth-weight prematurity: a place for an early operation?
European Journal of Cardio-Thoracic Surgery · 2024
DOI: 10.1093/ejcts/ezae175 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2024. Verfasst von Won Young Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic …. Hauptthemen laut MEDLINE: Ductus Arteriosus, Patent, Infant, Very Low Birth Weight, Ibuprofen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES The goal was to evaluate neonatal outcomes based on treatment strategies and time points for haemodynamically significant patent ductus arteriosus (hsPDA) in very-low-birth-weight preterm infants, with a particular focus on surgical closure. METHODS This retrospective study included very-low-birth-weight infants born between 2014 and 2021 who received active treatment for hsPDA. Neonatal outcomes were compared between (i) primary surgical closure versus primary ibuprofen; (ii) early (<14th post-natal day) versus late primary surgical closure (≥14th post-natal day); and (iii) primary versus secondary surgical closure after ibuprofen failure. Further analysis using 1:1 propensity score matching was performed. Logistic regression was conducted to analyse the risk factors for post-ligation cardiac syndrome (PLCS) and/or acute kidney injury (AKI). RESULTS A total of 145 infants with hsPDA underwent active treatment for closure. The in-hospital death rate and the incidence of severe bronchopulmonary dysplasia (BPD) were similar between the primary surgical closure group and the primary ibuprofen group in a 1:1 matched analysis. Severe BPD was significantly higher in the late surgical closure group than in the early primary surgical closure group with 1:1 propensity score matching (72.7% vs 40.9%, P=0.033). The secondary surgical closure group showed the mildest clinical condition; however, the probability of PLCS/AKI was highest (38.6%) compared to the early (15.2%) or the late primary surgical group (28.1%, P<0.001), especially in extremely premature infants (gestational age < 28 weeks). CONCLUSIONS Surgical patent ductus arteriosus closure is not inferior to pharmacologic treatment. Considering the harmful effect of a prolonged patent ductus arteriosus shunt exposure, a timely decision and timely efforts should be made to minimize the risk of severe BPD and PLCS/AKI after surgical closure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
ORCID-Profile: Won Young Lee, Sook Kyung Yum, Yu-Mi Seo, Sol Kim, Ju Ae Shin, Cheul Lee
Zitieren
APA
Lee, W. Y., Yum, S. K., Seo, Y. M., Kim, S., Shin, J. A., & Lee, C. (2024). Patent ductus arteriosus management in very-low-birth-weight prematurity: a place for an early operation?. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezae175
Vancouver
Lee WY, Yum SK, Seo YM, Kim S, Shin JA, Lee C. Patent ductus arteriosus management in very-low-birth-weight prematurity: a place for an early operation?. European Journal of Cardio-Thoracic Surgery. 2024. doi:10.1093/ejcts/ezae175
BibTeX
@article{Lee2024,
author = {Lee, Won Young and Yum, Sook Kyung and Seo, Yu-Mi and Kim, Sol and Shin, Ju Ae and Lee, Cheul},
title = {Patent ductus arteriosus management in very-low-birth-weight prematurity: a place for an early operation?},
journal = {European Journal of Cardio-Thoracic Surgery},
year = {2024},
doi = {10.1093/ejcts/ezae175}
}
EUVIMED